DelveInsight’s “Biliary Atresia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Biliary Atresia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Biliary Atresia market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Biliary Atresia: An Overview
Biliary Atresia is a condition in infants in which the bile ducts—tubes inside and outside the liver—are scarred and blocked. Bile ducts carry bile from the liver to the gallbladder for storage, and to the first part of the small intestine, also called the duodenum, for use in digestion. In infants with Biliary Atresia, bile can’t flow into the intestine, so bile builds up in the liver and damages it. The damage leads to scarring, loss of liver tissue and function, and cirrhosis.
There are two types of Biliary Atresia, a fetal form, which develops during fetal life and is present at birth, and a more common perinatal form, which does not become evident until the second to fourth week of the infant’s life.
Biliary Atresia Market Key Facts
According to the National Organization for Rare Disorders, Biliary Atresia occurs in approximately 1 in 10,000 to 15,000 births in the United States. Approximately 400-600 new cases of Biliary Atresia are encountered in the United States each year.
According to one estimate, the prevalence of Biliary Atresia in Europe is approximately 1 in 12,000 births.
As per the “American Liver Foundation”, up to 10-20% of infants with Biliary Atresia may have other associated malformations including multiple spleens, abnormal vessels supplying or draining the liver, or heart defects. About 75% of children with Biliary Atresia may eventually need a liver transplant.
As per Sokol (2009), the incidence of Biliary Atresia was found to be 1 in 13,000 live births in the United States, it is considered a rare disease; however, it is the indication for 40–50% of all liver transplants performed in children.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Biliary Atresia market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Biliary Atresia market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Biliary Atresia Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Biliary Atresia Epidemiology, Segmented as –
Incident cases of Biliary Atresia in the 7MM (2019–2032)
Type-specific Incident Cases of Biliary Atresia in 7MM (2019–2032)
Diagnosed and Treatable Cases of Biliary Atresia in 7MM (2019–2032)
Gender-specific Incident Cases of Biliary Atresia in 7MM (2019–2032)
Biliary Atresia Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Biliary Atresia market or expected to be launched during the study period. The analysis covers the Biliary Atresia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Biliary Atresia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Biliary Atresia Market Will Evolve and Grow by 2032 @
Biliary Atresia Therapeutics Analysis
The current pipeline for Biliary Atresia does not hold many significant products, it has very few products that are being developed by certain key players. Currently, Albireo Pharma is leading the therapeutics market with its Biliary Atresia drug candidates in the most advanced stage of clinical development.
Leading Players in the Biliary Atresia Therapeutics Market Include
And Many Others
Biliary Atresia Therapies Covered in the Report Include:
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Biliary Atresia Competitive Intelligence Analysis
4. Biliary Atresia Market Overview at a Glance
5. Biliary Atresia Disease Background and Overview
6. Biliary Atresia Patient Journey
7. Biliary Atresia Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Biliary Atresia Treatment Algorithm, Current Treatment, and Medical Practices
9. Biliary Atresia Unmet Needs
10. Key Endpoints of Biliary Atresia Treatment
11. Biliary Atresia Marketed Products
12. Biliary Atresia Emerging Drugs and Latest Therapeutic Advances
13. Biliary Atresia Seven Major Market Analysis
14. Attribute Analysis
15. Biliary Atresia Market Outlook (In US, EU5, and Japan)
16. Biliary Atresia Access and Reimbursement Overview
17. KOL Views on the Biliary Atresia Market
18. Biliary Atresia Market Drivers
19. Biliary Atresia Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Liver Angiosarcoma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Liver Angiosarcoma market trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan). Moreover, it covers the current treatment practices, emerging drugs, market share of individual therapies, treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Liver Angiosarcoma market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States